Article
Author: Kochman, Janusz ; Legutko, Jacek ; Smolka, Grzegorz ; Frank, Marek ; Grygier, Marek ; Dudek, Dariusz ; Wilczek, Krzysztof ; Grodecki, Kajetan ; Protasiewicz, Marcin ; Kleczyński, Paweł ; Huczek, Zenon ; Olszówka, Piotr ; Targoński, Radosław ; Wilimski, Radosław ; Hudziak, Damian ; Trębacz, Jarosław ; Wojakowski, Wojciech ; Lesiak, Maciej ; Sacha, Jerzy ; Milewski, Krzysztof ; Bartuś, Stanisław ; Dąbrowski, Maciej ; Hawranek, Michał ; Scisło, Piotr ; Parma, Radosław ; Witkowski, Adam ; Kralisz, Paweł ; Walczak, Andrzej
Over 15 years of clinical experience and multiple large-scale observational studies followed by guidelines show good safety and efficacy of valve-in-valve transcatheter aortic valve implantation TAVI (ViV-TAVI), which reduces the need for re-do surgical aortic valve replacement (SAVR) in high-risk patients. The number of procedures in Poland, estimated as ca. 2% of all TAVIs in 2020, is expected to rise. This article aims to review specific challenges of the ViV-TAVI procedure including proper pre-procedural planning to achieve best possible hemodynamic results and mitigate coronary occlusion risk. It also provides a preliminary review and guidelines on repeat TAVI (re-do TAVI) in patients presenting with a failed transcatheter aortic bioprosthesis.